Expression-targeted gene therapy for the treatment of transitional cell carcinoma

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Cancer Gene Therapy

• Publication date

  2008-03-07

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/cgt.2008.7PMID 18323852
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison of Caspase Genes for the Induction of Apoptosis Following Gene Delivery

  2009cited by this paper
• Expression of cyclooxygenase-2 in Hodgkin's lymphoma:its role in cell proliferation and angiogenesis

  2006cited by this paper
• Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma.

  2006cited by this paper
• Mediators of PGE2 synthesis and signalling downstream of COX-2 represent potential targets for the prevention/treatment of colorectal cancer.

  2006cited by this paper
• Expression of cyclooxygenase-2 related to angiogenesis in uterine cervical cancers.

  2006cited by this paper
• Inhibition of cyclooxygenase-2 disrupts tumor vascular mural cell recruitment and survival signaling.

  2006cited by this paper
• Cyclooxygenase-2 inhibitor, nimesulide, improves radiation treatment against non-small cell lung cancer both in vitro and in vivo.

  2006cited by this paper
• AdCD40L Gene Therapy Counteracts T Regulatory Cells and Cures Aggressive Tumors in an Orthotopic Bladder Cancer Model

  2005cited by this paper
• A Cox-2 Promoter-Based Replication-Selective Adenoviral Vector to Target the Cox-2-Expressing Human Bladder Cancer Cells

  2004cited by this paper
• Cell-specific expression of SERCA, the exogenous Ca2+ transport ATPase, in cardiac myocytes.

  2004cited by this paper
• Adenovirus CD40 Ligand Gene Therapy Counteracts Immune Escape Mechanisms in the Tumor Microenvironment1

  2004cited by this paper
• COX-2 and colorectal cancer.

  2003cited by this paper
• Nonviral cytokine gene therapy on an orthotopic bladder cancer model.

  2003cited by this paper
• A mechanistic role for cardiac myocyte apoptosis in heart failure.

  2003cited by this paper
• Directed apoptosis in Cox-2-overexpressing cancer cells through expression-targeted gene delivery

  2003cited by this paper
• In Vivo Targeting of Tumor Endothelial Cells by Systemic Delivery of Lentiviral Vectors

  2003cited by this paper
• Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer.

  2003cited by this paper
• The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy

  2003cited by this paper
• Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer.

  2003cited by this paper
• Organ-specific gene expression in the rhesus monkey eye following intravenous non-viral gene transfer.

  2003cited by this paper
• Caspase-9 transduction overrides the resistance mechanism against p53-mediated apoptosis in U-87MG glioma cells.

  2002cited by this paper
• Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells.

  2002cited by this paper
• Conditional cell ablation by tight control of caspase-3 dimerization in transgenic mice

  2002cited by this paper
• Expression of cyclooxygenase-2 in patients with bladder carcinoma.

  2001cited by this paper
• A new mathematical model for relative quantification in real-time RT-PCR.

  2001cited by this paper
• Adenovirus-mediated transfer of inducible caspases: a novel "death switch" gene therapeutic approach to prostate cancer.

  2001cited by this paper
• EXPRESSION OF CYCLOOXYGENASE‐1 AND‐2 IN URINARY BLADDER CARCINOMAS IN VIVO AND IN VITRO AND PROSTAGLANDIN E 2 SYNTHESIS IN CULTURED BLADDER CANCER CELLS

  2001cited by this paper
• Overexpression of cyclooxygenase-2 in squamous cell carcinoma of the urinary bladder.

  2001cited by this paper
• Expression of nitric oxide synthase, cyclooxygenase, and p53 in different stages of human gastric cancer.

  2001cited by this paper
• COX‐2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX‐2 inhibitor celecoxib

  2001cited by this paper
• Caspase-9 transduction overrides the resistance mechanism against p53-mediated apoptosis in U-87MG glioma cells. Commentaries

  2001cited by this paper
• Caspase-9 Transduction Overrides the Resistance Mechanism against p53-mediated Apoptosis in U-87MG Glioma Cells

  2001cited by this paper
• Increasing endothelial cell specific expression by the use of heterologous hypoxic and cytokine-inducible enhancers

  2000cited by this paper
• Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis.

  2000cited by this paper
• Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus.

  2000cited by this paper
• Transduction of Apaf-1 or caspase-9 induces apoptosis in A-172 cells that are resistant to p53-mediated apoptosis.

  2000cited by this paper
• Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer.

  2000cited by this paper
• Chemopreventive activity of celecoxib, a specific cyclooxygenase‐2 inhibitor, and indomethacin against ultraviolet light–induced skin carcinogenesis

  1999cited by this paper
• Improved Artificial Death Switches Based on Caspases and FADD

  1999cited by this paper
• Optimizing syngeneic orthotopic murine bladder cancer (MB49).

  1999cited by this paper
• Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing

  1999cited by this paper
• ICE family proteases in inflammation and apoptosis.

  1998cited by this paper
• Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis.

  1998cited by this paper
• ICE family proteases in inflammation and apoptosis.

  1998cited by this paper
• Cyclooxygenase regulates angiogenesis induced by colon cancer cells.

  1998cited by this paper
• Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity.

  1998cited by this paper
• Transcriptional targeting of replication-defective adenovirus transgene expression to smooth muscle cells in vivo.

  1997cited by this paper
• Molecular cloning and sequence analysis of a mouse Y chromosome RNA transcript expressed in the testis.

  1987cited by this paper

• Cyclic polymers: Advances in their synthesis, properties, and biomedical applications

  2020cites this paper
• Interested in publishing with us ? Contact book

  2019cites this paper
• Cancer‐specific promoters for expression‐targeted gene therapy: ran, brms1 and mcm5

  2016cites this paper
• Preclinical evaluation of VAX-IP, a novel bacterial minicell-based biopharmaceutical for nonmuscle invasive bladder cancer

  2016cites this paper
• The Synthesis of Cyclic Poly(ethylene imine) and Exact Linear Analogues: An Evaluation of Gene Delivery Comparing Polymer Architectures.

  2015cites this paper
• Preclinical evaluation of a gene therapy treatment for transitional cell carcinoma

  2011cites this paper
• Analysis of promoters and expression‐targeted gene therapy optimization based on doubling time and transfectability

  2011cites this paper
• An orthotopic model of murine bladder cancer.

  2011cites this paper
• Cancer cells can be tricked into self-destructing.

  2011cites this paper
• Gene Therapy in Urology

  2011cites this paper
• Células madre y medicina regenerativa en urología, 2.a parte: urotelio, vejiga, uretra y próstata

  2010cites this paper
• [Stem cells and regenerative medicine in urology, part 2: urothelium, urinary bladder, urethra and prostate].

  2010cites this paper
• miR-200 Expression Regulates Epithelial-to-Mesenchymal Transition in Bladder Cancer Cells and Reverses Resistance to Epidermal Growth Factor Receptor Therapy

  2009cites this paper